Psoriasis risk in children is influenced by genetics and environmental triggers. Learn about hereditary factors, symptoms, and ways to reduce flare-ups.

Psoriasis extends beyond the skin. Explore five key comorbidities, from psoriatic arthritis and cardiometabolic risk to mental health and ocular disease, to support comprehensive care.

Oct 23 (Reuters) - Britain's medicines regulator on Friday approved Johnson & Johnson's daily pill for adults and teenagers ...

There’s an interesting relationship between psoriasis and exercise: While the condition can make playing sports and working ...

Developing psoriasis didn’t exactly help with that internal dialogue. I began noticing symptoms when I was around 20, back in ...

A Japanese case report of co-localized psoriasis and vitiligo reveals that IL-23 blockade cleared psoriasis but not vitiligo, ...

Psoriasis can follow you into the bedroom, turning what should be an enjoyable moment into a worry about what someone might ...

An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics. Dose ...

GLP-1 receptor agonists are increasingly being studied for potential dermatologic applications due to their anti-inflammatory ...

Zasocitinib demonstrated superiority over deucravacitinib for the treatment of moderate to severe plaque psoriasis, according ...

The combination of medications also showed increased inflammatory immune activity.

AbbVie (NYSE: ABBV), announced today that Health Canada has approved SKYRIZI® (risankizumab) for the treatment of pediatric patients aged 6 to <18 years of age with moderate to severe plaque psoriasis ...